RxDoctor Payments Data

Sarwat Umer, MD

Internal Medicine · Teaneck, NJNPI 1033186200

Payments from drug & device makers

$6,277in general payments, 2019–2025

Across 295 payments — averaging $21.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Boehringer Ingelheim$996
  • Amgen$984
  • AstraZeneca$941
  • GSK$356
  • Lilly USA, LLC$252
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$6,266100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,277 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$176,234
Medicare patients
123
Services billed
2,512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin70$94,465
OzempicSemaglutide32$45,011
JanuviaSitagliptin Phosphate42$41,204
EliquisApixaban24$25,140
TradjentaLinagliptin11$15,260
LinzessLinaclotide11$10,382
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$9,873
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,744
XareltoRivaroxaban12$9,631
NamzaricMemantine Hcl/Donepezil Hcl11$7,407
Duloxetine Hcl54$2,438
Nebivolol Hcl16$2,430
Atorvastatin Calcium215$2,118
Rosuvastatin Calcium76$1,709
Ezetimibe34$1,425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$996$109,72581 claims
Novo NordiskOzempic$1,574$45,01132 claims
MerckJanuvia$71$41,20442 claims
PfizerEliquis$152$25,14024 claims
AbbVieLinzess, Namzaric$13$17,78922 claims
AstraZenecaBreztri Aerosphere$941$9,87313 claims
GSKTrelegy Ellipta$356$9,74414 claims
Johnson & JohnsonXarelto$102$9,63112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Teaneck

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →